Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Knuth

Showing results (171-180 of 189) with videos related to

Pageof 19
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 12, 2000
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancersE Jäger, S Gnjatic, Y Nagata, et al.
International Journal of Cancer|October 3, 1999
Antigens recognized by autologous antibody in patients with renal-cell carcinomaM J Scanlan, J D Gordan, B Williamson, et al.
Scandinavian Journal of Immunology|September 1, 1996
Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gammaH Bernhard, M J Maeurer, E Jäger, et al.
European Cells & Materials|September 19, 2019
Collagen type X is essential for successful mesenchymal stem cell-mediated cartilage formation and subsequent endochondral ossificationC A Knuth, E Andres Sastre, N B Fahy, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 27, 2000
Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I alleleS Gnjatic, Y Nagata, E Jager, et al.
Annals of Hematology|May 25, 2004
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemiaW K Hofmann, G Heil, C Zander, et al.
British Journal of Cancer|September 11, 2003
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trialC-H Köhne, R Catane, B Klein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study GroupE Laack, N Dickgreber, T Müller, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 26, 2000
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responsesE Jäger, Y Nagata, S Gnjatic, et al.
Cancer Science|March 1, 2008
MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcomeM Tinguely, B Jenni, A Knights, et al.
Pageof 19

Showing results (171-180 of 189) with videos related to

Sort By:
Pageof 19
Proceedings of the National Academy of Sciences of the United States of America|October 12, 2000
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancersE Jäger, S Gnjatic, Y Nagata, et al.
International Journal of Cancer|October 3, 1999
Antigens recognized by autologous antibody in patients with renal-cell carcinomaM J Scanlan, J D Gordan, B Williamson, et al.
Scandinavian Journal of Immunology|September 1, 1996
Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gammaH Bernhard, M J Maeurer, E Jäger, et al.
European Cells & Materials|September 19, 2019
Collagen type X is essential for successful mesenchymal stem cell-mediated cartilage formation and subsequent endochondral ossificationC A Knuth, E Andres Sastre, N B Fahy, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 27, 2000
Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I alleleS Gnjatic, Y Nagata, E Jager, et al.
Annals of Hematology|May 25, 2004
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemiaW K Hofmann, G Heil, C Zander, et al.
British Journal of Cancer|September 11, 2003
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trialC-H Köhne, R Catane, B Klein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study GroupE Laack, N Dickgreber, T Müller, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 26, 2000
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responsesE Jäger, Y Nagata, S Gnjatic, et al.
Cancer Science|March 1, 2008
MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcomeM Tinguely, B Jenni, A Knights, et al.
Pageof 19